Back to top
more

Puma Biotechnology (PBYI)

(Real Time Quote from BATS)

$2.98 USD

2.98
78,475

+0.03 (1.02%)

Updated Nov 4, 2024 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.

Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA

by Zacks Equity Research

The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.

CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%

by Zacks Equity Research

CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

by Zacks Equity Research

Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.

Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis

by Zacks Equity Research

The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.

Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev

by Zacks Equity Research

The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.

Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EU

by Zacks Equity Research

Biogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older.

Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study

by Zacks Equity Research

Reneo (RPHM) loses 83% following the failure of the mid-stage pivotal study of its only pipeline candidate, mavodelpar, to treat primary mitochondrial myopathies in adults. It cuts the workforce by 70%.

Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA

by Zacks Equity Research

The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.

Acadia (ACAD) Rises 35% on Positive Patent Ruling for Nuplazid

by Zacks Equity Research

Acadia (ACAD) announces a ruling from the U.S. District Court in Delaware, strongly in favor of the company for its patent for Nuplazid. The stock surges 35% in response.

Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC

by Zacks Equity Research

Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.

Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up

by Zacks Equity Research

Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.

C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck

by Zacks Equity Research

C4 Therapeutics (CCCC) inks an agreement with Merck to discover and develop degrader-antibody conjugates with a focus on one oncology target. Shares rise on the same.

Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409

by Zacks Equity Research

The FDA gives Fast Track designation to Candel's (CADL) lead candidate, CAN-2409 plus prodrug (valacyclovir), for the treatment of patients with pancreatic cancer.

Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why

by Zacks Equity Research

Biomea Fusion (BMEA) rises 41% in a month on the back of positive investor expectations regarding the clinical development of its lead candidate, BMF-219, for the type II diabetes indication.

Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects

by Zacks Equity Research

Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.

GSK's Jemperli Gets EU Nod for Endometrial Cancer Expanded Use

by Zacks Equity Research

GSK's Jemperli combo receives the European Commission's marketing authorization as a frontline treatment for certain types of primary advanced/recurrent endometrial cancer.

Pfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EU

by Zacks Equity Research

Pfizer's (PFE) targeted immunotherapy, Elrexfio, for treating heavily pretreated adults with relapsed/refractory multiple myeloma gets EC's conditional marketing authorization.

Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails

by Zacks Equity Research

The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.

CRISPR (CRSP), Vertex Fall Despite FDA Nod to SCD Drug Casgevy

by Zacks Equity Research

CRISPR (CRSP) and Vertex announce the FDA approval of the first-ever CRISPR-based gene-editing therapy, Casgevy, for the treatment of sickle cell disease.

Vaishali Doshi headshot

Snap These 4 Top-Performing Liquid Stocks for Strong Returns

by Vaishali Doshi

Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), DropBox (DBX) and GigaCloud Technology Inc. (GCT), which investors can add to their portfolio for solid gains.

Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474

by Zacks Equity Research

Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.

Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study

by Zacks Equity Research

Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.

Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene

by Zacks Equity Research

Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.

Journey Medical (DERM) Up on Update for Skin Disease Candidate

by Zacks Equity Research

Journey Medical (DERM) plans to submit a new drug application (NDA) to the FDA for DFD-29 to treat rosacea in adults by 2023-end. Stock rises.